On the Horizon: Expert Insights Into New and Emerging Novel ADCs for the Treatment of Advanced Solid Tumors

Release Date: May 31, 2024 
Expiration Date: May 31, 2025
Time to Complete Activity: 1.25 hours


Petros Grivas, MD, PhD
Division of Hematology Oncology, Dept of Medicine 
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
UW Medicine
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA

Paolo Tarantino, MD
Advanced Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Helena A. Yu, MD
Research Director, Thoracic Oncology Service
Associate Attending 
Memorial Sloan Kettering Cancer Center
New York, NY

Target Audience 

This activity has been designed to address the educational needs of clinicians involved in the treatment of patients with or at risk for advanced solid tumors, including oncologists, pathologists, pulmonologists, and clinical investigators.

Educational Provider 

This activity is provided by Paradigm Medical Communications, LLC.  

Supporter Acknowledgment 

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Program Overview 

Although antibody-drug conjugates (ADCs) are available for oncology care, the field of new and emerging novel ADCs is expanding rapidly. Many are in various stages of development for treatment of advanced solid tumors, and even though their general mechanisms are similar, the specific targets and rationales underlying each agent differ, making it challenging for oncology clinicians to remain up to date on development status, clinical trial data, and any new or potential approvals. This activity will highlight expert insights on new and emerging novel ADCs to enable clinicians to incorporate these agents into patient care in the clinical trial setting or once they are approved.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Outline the rationale for developing ADCs against novel targets with regard to their mechanisms of action and the pathophysiology of advanced solid tumors
  • Describe the latest clinical trial data for new and emerging ADCs, including efficacy data and status of ongoing studies
  • Review the safety profiles of new and emerging ADCs based on the latest clinical trial data

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education 

PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Hardware/Software Requirements

This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support
If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Instructions for Participation

To receive a certificate of participation, participants must:

  • Follow instructions to register or log in with your professional information and complete the pretest
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.

Disclosure of Relevant Financial Relationships

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Petros Grivas, MD, PhD
Consultant: Aadi Bioscience, Inc.; AbbVie Inc.; Asieris Pharmaceuticals; Astellas Pharma US, Inc; AstraZeneca; BostonGene Corporation; Bristol-Myers Squibb Company; CG Oncology; Dyania Health; F. Hoffmann-La Roche AG; Fresenius Kabi AG; G1 Therapeutics; Gilead Sciences, Inc.; Guardant Health, Inc.; ImmunityBio, Inc.; Janssen Pharmaceuticals, Inc; Lucence Health Inc.; Merck & Co.; Merck KGaA; Pfizer Inc; PureTech Health; Seagen Inc.; Strata Oncology, Inc.; Silverback Therapeutics
Research Funding: Acrivon Therapeutics; ALX Oncology Inc.; Bristol-Myers Squibb Company; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Merck & Co.; Merck KGaA; Mirati Therapeutics, Inc.; Pfizer Inc (all funds paid to institution)

Paolo Tarantino, MD
Advisor: AstraZeneca; Daiichi Sankyo Company, Limited; Eli Lilly and Company; Genentech, Inc; Gilead Sciences, Inc.; Novartis AG
Research Funding: AstraZeneca

Helena A. Yu, MD
Consultant: Amgen Inc; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Cullinan Oncology, LLC; Daiichi Sankyo Company, Limited; Janssen Pharmaceuticals, Inc; Novocure; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Company Ltd
Research Funding: AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Cullinan Oncology; Daiichi Sankyo Company, Limited; Erasca; Janssen Pharmaceuticals, Inc; Pfizer Inc; Systimmune, Inc. (all funds paid to medical institution)

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com

© 2024 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.